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Abstract 1 
Treatment by the pulmonary route can be used for administration of drugs that act 2 
locally in the lungs (e.g. treatment of lung cancer, chronic obstructive pulmonary 3 
disease, asthma) or non-invasive administration of drugs that act systemically.  The 4 
potential of drug delivery systems formed from non-ionic surfactants or natural 5 
products i.e. proteins and polysaccharides for pulmonary delivery are discussed.   6 
  7 
Introduction 8 
 9 
Treatment by inhalation can be used to deliver drugs directly to the lungs to treat 10 
conditions such as lung cancer, tuberculosis, cystic fibrosis or asthma; or as a means 11 
of treating systemic conditions such as diabetes or analgesia and the pulmonary drug 12 
delivery market is estimated to be worth £28.7million by 2019 [1].  Treatment by 13 
inhalation is more patient friendly than parenteral injection. It also allows the drug to 14 
avoid the first pass metabolism which occurs in the liver, and the concentration of 15 
metabolising enzymes such as CYP450 is lower in the lungs compared to other organs 16 
[2]. However successful drug delivery via this route requires production of a drug 17 
formulation that is effective, stable and safe but it must also be suitable for inhalation 18 
and have the correct characteristics to reach the appropriate site within the lungs.  19 
Additionally a drug must evade the innate defense mechanisms present in the lungs, 20 
such as mucociliary clearance and macrophage uptake before it reaches its site of 21 
action [3]. The lungs are primarily designed for gas exchange and have a symmetric 22 
dichotomously branching structure (Figure 1). The upper respiratory tract consists of 23 
the nasal cavity and pharynx and the lower respiratory tract consists of the larynx, 24 
trachea, bronchi, bronchioles and alveoli [4]. The surface area of the lungs increases 25 
from 2 m2 in the upper respiratory tract to 103 m2 in the lower airways. And cell 26 
thickness decreases from 60 µm in the bronchi to 0.1 µm in the alveoli. Aerosol particle 27 
size is a key parameter in defining the drug deposition within the lungs. Aerosols with 28 
a small particle size (< 2 µm) are distributed in the peripheral airways, whereas larger 29 
aerosols (> 5 µm) are deposited in the central area of the lungs. Particles are deposited 30 
in the lungs by inertial impaction, gravitational sedimentation or Brownian diffusion. 31 
Inertial impaction predominates, as large particles (> 10 µm) cannot follow the fast 32 
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airflow in the conducting airways, and impact into the walls of the upper 33 
tracheobronchial region. Particles that impact on the mucus barrier are then cleared 34 
by the mucociliary escalator system, where ciliated epithelium moves mucus 35 
entrapped particles towards the pharynx where they are removed by macrophages or 36 
expectorated [5]. Smaller aerosol particles (< 5 µm) sediment in the bronchi and 37 
bronchioles or reach the alveoli, where they are exposed to Brownian diffusion as the 38 
air velocity is negligible within the alveoli. Thus aerosol particles between 1 and 5 µm 39 
can reach the lower respiratory system [6]. Very small particles (< 0.1 µm) cannot be 40 
deposited in the airways as they are breathed out easily [7]. The optimal site of aerosol 41 
deposition depends on the particular application. For instance, ƚŚĞ ɴ2 agonist 42 
ƐĂůďƵƚĂŵŽůƐŚŽƵůĚďĞĚĞůŝǀĞƌĞĚƚŽƚŚĞƉĞƌŝƉŚĞƌĂůĂƌĞĂƐŽĨƚŚĞůƵŶŐƐĂƐɴ2 receptors are 43 
located in the bronchi and bronchioles [8] whereas the muscarinic antagonist 44 
ipratropium bromide, should be deposited in the conducting airways as muscarinic 45 
M3 receptors are predominant in the conducting airways [9]. For the treatment of 46 
systemic diseases, the inhaled drug should be deposited in the peripheral areas that 47 
are rich in alveoli, where systemic absorption is facilitated by the thin alveolar-vascular 48 
barrier [10]. Drug deposition can also be influenced by pathological 49 
bronchoconstriction, inflammation or airway obstruction, leading to uneven or central 50 
deposition of the drug formulation within the respiratory tract [11, 12].  51 
 52 
 53 
 5 
 54 
Figure 1 Areas of the respiratory system based on physiological characteristics or 55 
anatomical parts. Inhaled aerosols are deposited in different areas of the respiratory 56 
system according to their droplet size (adapted [10,13,14]). 57 
 58 
 59 
Influence of the inhalation device 60 
The development of an effective inhaled therapy depends on the pharmacology of the 61 
active ingredients, its aerosolisation characteristics and the efficiency of the aerosol 62 
generating device e.g. pressurised metered-dose inhaler, dry powder inhaler or 63 
nebuliser. There are a wide range of pulmonary devices [15] and new generation 64 
inhalers are very efficient at producing aerosols with well characterised properties. 65 
Thus has lead to more effective targeting of the nebulised drug formulation to the 66 
lungs, which can lead to the development of a specialised drug-device combination 67 
for a particular application. Some inhalers have ĂĚĚĞĚĂĚĂƉƚŝŽŶƐƚŽŝŶĐƌĞĂƐĞ ?ease of 68 
use ? ?ǁŚŝĐŚŝƐŽĨƉĂƌƚicular importance for therapies directed towards patients with an 69 
older patient profile, or the ability to obtain data on the dose delivered to the patient 70 
[16].  71 
 72 
It is possible to measure the aerosol particle size in vitro using an impactor, where an 73 
aerosol hits a flat surface and is separates into different size ranges depending on 74 
where it lands in the impactor or impingers. The newest impactor described in the 75 
European Pharmacopoeia is the next generation impactor (NGI), which is the only 76 
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impactor that works horizontally and collects the aerosol droplets on cups of different 77 
cut-off diameter. It has seven stages and a micro orifice collector. The European 78 
Pharmacopoeia describes one twin and three multistage apparatus [17]. The twin 79 
impinger is operated at a flow rate of 60 L/min and has a cut-off diameter of 6.4 µm. 80 
This meaning that particles found in the second stage correspond to the respirable 81 
portion (< 6.4 µm). The multi-stage liquid impinger (MSLI), can be used at different air 82 
flows, and has a mouth piece attached to the aerosol device, 4 stages and filter paper 83 
in the fifth compartment collects the remaining particles. The advantage of the MSLI 84 
over other impactors is the presence of solvent in each collection stage. This is 85 
important, as it avoids the re-entrainment phenomena of aerosol droplets being 86 
reincorporated into the airflow, particularly with DPIs. The data obtained using any of 87 
the multi-stage impingers or impactors can be used to calculate the aerodynamic 88 
aerosol size distribution of an aerosolised formulation. The mass median aerodynamic 89 
diameter (MMAD) of an active ingredient is the diameter at which 50 % of the particles 90 
by mass are bigger than the other 50 %. The MMAD is calculated when the log-normal 91 
distribution of the mass-weighted data is assumed by plotting a base ten logarithm 92 
cut-off diameter against cumulative percentage undersize [18]. The distribution of the 93 
particles in the apparatus is generally described by the geometric standard deviation 94 
(GSD) and a GSD closer to the one indicates a mono-distributed aerosol size. Fine 95 
particle fraction (FPF < 5 µm) is the fraction of the aerosol mass contained in particles 96 
with an aerodynamic diameter smaller than 5 µm and larger than 0.98 µm. Achieving 97 
a low MMAD and a GSD close to the one indicates a fine aerosol size with a tight size 98 
distribution. However, the aerodynamic aerosol size distribution calculated with 99 
impactor techniques can only be classified into a small number of size ranges 100 
depending on the number of stages of the apparatus. For example, the twin impactor 101 
possesses one cut-off diameter and the NGI seven. Electrostatic charge and fine 102 
particle adhesion on the walls of the apparatus and losses between stages may also 103 
disturb particle collection. Another way to characterize aerosol characteristics is to 104 
use laser diffraction techniques. These are easy-to-use and can analyse particles over 105 
a broad size range. In addition, the measurement is fast, non-flow dependent and 106 
possess automatic data recording. A unique characteristic of laser diffraction methods 107 
is being able to carry out time measurements of the cloud distribution [19] and analyse 108 
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multi-modal drop size aerosol distribution [20]. However, low particle concentration 109 
may lead to low laser obstruction so the aerosol cloud may not be able to be 110 
measured. Laser diffraction does not measure aerodynamic diameter. Instead, it 111 
measures geometric diameter in terms of mass median diameter (MMD). This value 112 
does not consider particle density and assumes that particles are spherical. Pilcer et 113 
al. [21] compared the values of respiratory fraction obtained with MSLI and the NGI 114 
with the values acquired from laser diffraction techniques when powder formulations 115 
were aerosolised. The data obtained from the impactor and the laser diffraction 116 
differed. However, they found a good correlation factor between both aerodynamic 117 
diameter and geometric diameter results. 118 
 119 
Animal studies  120 
Animal models have been extensible used to investigate the effect of inhaled drug 121 
therapies [22, 23]. However, the physiology of the human airways is spherical with 122 
symmetric branching, and these features are not present in other species [24]. 123 
Moreover, breathing pattern and obligate nose breathing in rodents are also distinct 124 
from humans [12, 25, 26]. Despite those differences, Schlesinger [27] demonstrated a 125 
similar relationship between aerosol size and lung deposition in humans and animals 126 
such as are dogs, rats, guinea pigs, hamsters and mice. However, alveolar distal 127 
impaction reached a peak between 2 and 4 µm in humans but experimental animals 128 
have a peak nearer 1 µm. Some researchers have used mathematic models to study 129 
the aerosol distribution in the airways as an alternative to in vivo models [28] but these 130 
methods are highly complex and may not reflect all the conditions that occur in vivo. 131 
Imaging techniques, have been used to give a more accurate picture of drug 132 
deposition e.g. radiolabelled inhaled drugs detected by scintigraphic studies [29], 133 
positron emission tomography imaging [30], magnetic resonance imaging [31] or 134 
fluorescent imaging [32]. It is now possible to use a combination of imaging methods 135 
to improve the signal and in vivo detection of a system. For example using quantum 136 
dots, which emit a strong fluorescent signal that is not photobleached, coupled with 137 
MRI provides better visualisation than MRI alone [33]. In our studies we have used 138 
luciferin loaded non-ionic surfactant vesicles to show that the drug delivery system 139 
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(DDS) significantly improves in vivo targeting of luciferin to luciferase-expressing cells 140 
within the body.  141 
 142 
 
A- Luc-sol; 3.62 ± 0.33 p/s 
 
B- Luc-NIVs; 15.24 ± 2.94 p/s *** 
C  
Figure 2 Delivery of luciferin solution (A) compared to luciferin loaded nanocarriers (B; 143 
non-ionic surfactant vesicles, NIVs) to luciferase-expressing cells. Mice, infected 144 
intravenously with 2 x 107 luciferase-expressing Leishmania donovani promastigotes, 145 
were imaged with luciferin solution (5 mg/ml luciferin in PBS pH 7.4) or luciferin NIVs 146 
(30 mM lipid, 5 mg/ml luciferin in PBS pH 7.4). Bioluminescence was observed using 147 
IVIS imaging system (PerkinElmer, London UK) and represented as photons emitted 148 
per second (C).  Treatment with luciferin-NIV delivered significantly more luciferin to 149 
the luciferase-ĞǆƉƌĞƐƐŝŶŐƉĂƌĂƐŝƚĞƐĂƚƚŚŝƐƚŝŵĞƉŽŝŶƚ ?ƉA? ? ? ? ? ? ) ? 150 
 151 
Drug delivery systems  152 
Incorporation of drugs into a DDS can improve their therapeutic efficacy by directing 153 
a drug to the correct site for uptake. The lungs are rich in macrophages and 3% of the 154 
cells in the alveolar region are alveolar macrophages and recent studies indicate that 155 
lung macrophages self-renew in situ and can repopulate locally after tissue damage 156 
[35]. Macrophages clear particles from the circulation and using a nanoparticulate 157 
DDS will favour macrophage uptake in macrophage-rich tissues and away from urinary 158 
excretion [36, 37]. DDS can be produced in different forms to suit a particular clinical 159 
condition being treated and/or the route of administration e.g. capsules, vesicular 160 
formulations or nanoparticles (NP) and from different constituents e.g. chemically 161 
synthesized or natural products.   This review will only consider two types of DDS; 162 
namely non-ionic surfactant vesicles (NIV), and nanoparticles prepared from natural 163 
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polymers, for pulmonary delivery. There are excellent reviews on using types of DDS 164 
for pulmonary delivery that may be of interest [37, 38, 39].   165 
 166 
Non-ionic surfactant vesicles as a DDS 167 
The properties of NIV depend on their constituents, the relative molar ratio of the 168 
constituents and the method used to prepare the NIV. The inclusion of cholesterol 169 
into NIV helps stabilise the vesicular membrane and modifying the concentration of 170 
cholesterol present in the formulation influences drug loss across the vesicular bilayer.  171 
Inclusion of an amphiphile such as dicetyl phosphate, gives the vesicles a net negative 172 
surface charge, which helps to keep the vesicle dispersed within a suspension and 173 
prevents them clumping [40].   NIV have been used for delivery of a variety of drugs 174 
and hydrophilic drugs are entrapped within the aqueous space formed by the vesicle 175 
bilayers whereas hydrophobic drugs can be incorporated into the lipid bilayers.  NIV 176 
can be formed from a single or multiple bilayers depending on the production method.  177 
And the size of the vesicles formed can be reduced using different methods post-178 
production e.g. sonication, extrusion under high pressure or homogenisation. In our 179 
studies we have used rodent model of visceral leishmaniasis (VL), where animals 180 
infected with the protozoan parasite Leishmania donovani, allowed us to study drug 181 
delivery to the spleen, liver and bone marrow in the same animal [34]. In addition, this 182 
model allowed us to investigate local delivery to macrophages as the parasite lives 183 
with macrophages within these sites. We used reduction in parasite burdens as well 184 
as determining antimony levels within tissues as a measure of drug delivery.  This was 185 
particularly useful as SSG is a highly water soluble drug and has a short half life. VL is 186 
an important neglected tropical disease, which causes 40,000 deaths/year in the 187 
Indian subcontinent, would benefit from the production of more effective drug 188 
formulations, as there are a limited number of drugs available for treatment [41].  At 189 
present there is only one oral drug licenced for treatment of VL i.e. miltefosine, and 190 
resistance to miltefosine can easily be induced in the laboratory by culturing the 191 
parasite in medium containing increasing amount of miletfosine. Therefore, there is 192 
growing concern that the clinical utility of miltefosine may follow the same path as 193 
SSG especially as incidences of increased resistance to this drug have already been 194 
reported in India [42] and Nepal [43].   195 
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 196 
In our initial studies we showed that the NIV could be used to entrap the anti-197 
leishmanial drug, sodium stibogluconate (SSG), and that the amount of drug 198 
entrapped within vesicles significantly affected their in vivo efficacy in different sites. 199 
Thus treatment with SSG-NIV at a dose of 44.4 mg Sbv/kg resulted in a significant 200 
reduction in spleen, liver and bone marrow parasite burdens, but only if multiple 201 
doses (i.e. 5 doses) were used [44]. Similar treatment with SSG solution could only 202 
suppress liver parasites burdens in infected mice.  Determination of antimony levels 203 
showed that treatment with SSG-NIV resulted in significantly lower blood levels than 204 
similar treatment with free SSG solution and significantly higher amounts of antimony 205 
were detected in the liver at 6 days post-dosing [36]. Increasing the SSG concentration 206 
to prepare SSG-NIV increased the efficacy of the formulation.  Thus,  single dose 207 
treatment with SSG-NIV, prepared using SSG solution at 33 mg Sbv/ml, significantly 208 
suppressed parasite burdens (> 98% compared to controls) in all three sites when 209 
animals were treated with a dose of 296 mg Sbv/kg. In contrast similar treatment with 210 
SSG solution only affected hepatic parasite burdens.  This SSG-NIV formulation did not 211 
require sonication to reduce vesicle size. It was as effective as AmBisome, a liposomal 212 
formulation of amphotericin [45], and was highly active against clinical strains of 213 
antimony susceptible and antimony resistant L. donovani in murine studies [46].  214 
Studies in the dog were carried out to compare the pharmacokinetic and toxicity 215 
profile of SSG solution, SSG-NIV, SSG-dextan solution, and a SSG-NIV-dextran 216 
formulation. The SSG-NIV-dextran formulation was produced using an additional 217 
ultrafiltration step to remove unentrapped SSG, and the dextran was used to balance 218 
the osmotic pressure across the vesicle bilayer, which could result in loss of entrapped 219 
drug. The mean vesicle size was lower for the SSG-NIV-dextran solution and the 220 
entrapment efficiency was seven times higher (mean size: SSG-NIV, 526 nm, SSG-NIV-221 
dextran 253 nm; entrapment efficiency, SSG-NIV, 6%, SSG-NIV-dextran 43%).  222 
Treatment of dogs with a single intravenous dose of the four SSG formulations (10 mg 223 
Sbv/kg) showed that the SSG-NIV-dextran formulation gave a significantly highest 224 
distribution half-life (p = 0.01), longest elimination half-live (t ? ? ?ɴ) and a significantly 225 
higher residence time (p = 0.02). There were signs of acute toxicity in dogs treated 226 
with this formulation but not the SSG-NIV formulation, but these were short lived and 227 
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are probably related to the proportionally higher antimony dose directed to the liver 228 
but the formulation.  These could be avoided by simply reducing the drug dose. The 229 
toxic side effects were those expected for antimony and are unlikely to be related to 230 
the DDS as they were absent in dogs treated with the SSG-NIV formulation. Studies 231 
using the same formulations in mice showed that the SSG-NIV-dextran formulation 232 
was more effective than SSG or SSG-NIV even though it was given at a seventh of the 233 
drug dose  (33 versus 222 mg Sbv/kg, [47]). However further development of the SSG-234 
NIV formulation was stopped when antimony resistance developed within endemic 235 
parasites became widespread in India, as this may have affected the clinical utility of 236 
this formulation.  However, this did not stop development of this DDS as we had 237 
already demonstrated that NIV could be used to increase the in vivo efficacy of other 238 
drugs with different physiochemical characteristics [48, 49]. Over the years we have 239 
changed the method used to prepare NIV from a solvent based method to a simple 240 
 ?ŵĞůƚ-ŵĞƚŚŽĚ ?ǁŚĞƌĞƚŚĞǀĞƐŝĐƵůĂƌĐŽŶƐƚŝƚƵĞŶƚƐ ?ƐƵƌĨĂĐƚĂŶƚ ?ĐŚŽůĞƐƚĞƌŽů ?ĂŶĚĚŝĐĞƚyl 241 
phosphate) were melted at 130°C and then hydrated with drug solution at a 242 
temperature of 70°C.  We have used homogenisation at different speeds, and for 243 
different periods of time, to reduce vesicle size and we have produced vesicle 244 
suspensions with different means sizes (100-2000 nm range). We have identified a 245 
production method that is suitable for large-scale manufacture, and we have 246 
produced litre batches of NIV drug suspensions.  247 
 248 
The studies on formulating NIV drug formulations for the intravenous route have 249 
helped us develop NIV formulations for administration by the pulmonary route.  Using 250 
an amphotericin-NIV formulation (AMB-NIV) as our exemplar we have shown that 251 
treatment of rats infected with Aspergillus, an important human pathogen, resulted 252 
in a significant reduction in fungal lung burdens (p < 0.01).  One dose of AMB-NIV was 253 
as effective as 5 oral doses of the antifungal drug posaconazole [34].  Treatment with 254 
inhaled AMB-NIV resulted in significant higher levels of AMB in the lungs (p < 0.05) 255 
that similar treatment with AMB solution and significantly lower plasma levels (p < 256 
0.05).  This formulation was also active against L. donovani in a murine model when 257 
given by inhalation. Thus treatment with five doses of AMB-NIV resulted in a 258 
significant reduction in liver parasite burdens (p < 0.05) but failed to affect splenic or 259 
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bone marrow burdens compared to controls, the inability to affect parasites in deeper 260 
tissues probably reflects poor drug delivery to these sites.  Similar studies using mice 261 
infected in the footpad with luciferase-expressing L. major, a species that causes 262 
cutaneous leishmaniasis, showed that NIV did not enhance delivery of luciferin to 263 
parasites at this site based on bioluminescence emitted from the footpad after 264 
treatment.  Therefore, it was not surprising that treatment with inhaled AMB-NIV 265 
failed to reduce parasite burdens at this site compared to control values.  One of the 266 
problems associated with using the murine model is the practical difficulty 267 
encountered in treating mice by inhalation.  In our studies we have exposed mice to 268 
drug formulation by placing them in a Volumetric Spacer, and introducing aerosolised 269 
drug formulations produced using a Buxco® nebulisation system into the Spacer.  270 
Simple calculation of the drug dose administered using the breathing rate of mice 271 
indicates that only a fraction of a dose given is likely to be inhaled by mice. Thus 272 
calculation of the best-case scenario indicated that mice would inhale 17% of the drug 273 
dose given.  It is likely to be much lower, mice given luciferin-NIV by inhalation emitted 274 
< 4% of the bioluminescence emitted by mice given the same dose of luciferin-NIV by 275 
the intravenous route [34].  Despite this limitation this model can be used for initial 276 
screening of inhaled formulation, but ideally a larger rodent model should be used in 277 
studies.  Other researchers have also determined the feasibility of NIV prepared from 278 
a different surfactant for pulmonary delivery of beclomethasone dipropionate (BPD). 279 
The amount of drug entrapped within BDP-NIV increased as the drug concentration 280 
used to prepare NIV was increased, which is consistent with our findings.   The BPD-281 
NIV had a MMAD of 2 µm indicating that the NV would deposit within the lower 282 
airways of the lungs.  In addition, drug permeation studies indicated that the presence 283 
of the non-ionic surfactant increased the ability of the drug to pass through mucin, 284 
using an in vitro system [50].  Niosomes (or NIV) containing 5-fluorouracil which were 285 
prepared using different sorbitan monoesters had a mean size of 3.9-8.1 µm, making 286 
some of them too large for inhalation and the smaller ones would be difficult to 287 
aerosolise in a droplet size of < 5 µm required for delivery into the lower airways. 288 
However, another option would be to produce lyophilised formulations that could be 289 
administered as a dry powder using a suitable inhaler.   On reaching their deposition 290 
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site within the lungs the NIV constituents would be hydrated and vesicles, which 291 
would be taken up by the macrophages present [39].   292 
 293 
Nanoparticles produced from natural polymers as a DDS 294 
A different type of DDS to NIV are nanoparticles, which can give have high drug loading 295 
and are also readily taken up be aveolar macrophages [39].  NP can be produced from 296 
biocompatible polymers from natural proteins or sugars.  These types of formulations 297 
are often produced as a lyophilised product and administered using a dry powder 298 
inhaler.  This usually requires inclusion of a carrier into the formulation such as lactose, 299 
which prevents the NP clumping together.  However, by selecting an appropriate 300 
inhaler e.g. Turbuhaler® it is possible to remove the requirement for a carrier in the 301 
NP formulation [51]. 302 
 303 
 Three natural proteins can be used to produce NP: collagen, albumin or gluten. 304 
Production of collagen NPs usually requires the use of solvents and a multi-step 305 
method, which would increase manufacture costs. Electrospray methods can be used 306 
but these need to be adapted to ensure that particles rather than fibres are produced 307 
[52]. Collagen NP with a size of < 1 µm were produced when a salt solution as well as 308 
acetic acid at a concentration of < 90% v/v was used. Inclusion of the salt allowed 309 
formation of dried NP particle after spraying and increased the conductivity of the 310 
particles produced. Scanning electron studies showed that changing the salt solution 311 
(i.e sodium chloride vs. calcium chloride), the relative concentration of salt and/or 312 
acetic acid allowed NP with mean sizes between 228-900 nm to be formed. Loading 313 
collagen NP with theophylline, a drug used in the treatment of chronic obstructive 314 
pulmonary disease, resulted in the production of larger particles (size range of 2-3 315 
µm).  And factors such as type of nozzle used (single or coaxial), or cross-linking by 316 
exposing the formulation to glutaldehyde, influenced NP size; and the amount of 317 
cross-linking introduced influenced drug release. No in vivo studies were completed 318 
in this study but it did show that collagen nanoparticles of a suitable size range for 319 
lung delivery could be produced using a single step method. 320 
 321 
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Albumin NP can be produced using ovalbumin, serum albumin or human albumin.  322 
Human albumin is the most appropriate for clinical drug formulations, as it would not 323 
induce an immune response [53]. Choi and co workers [54] prepared NP using human 324 
serum albumin (HSA) conjugated with doxorubicin and octyl aldehyde. The NP were 325 
coated with TRAIL protein (tumour necrosis factor (TNF)-related apoptosis-inducing 326 
ligand) to improve drug targeting to cancer cells and had a particle size of 342 nm. The 327 
formulation was introduced into the lungs of nude BALB/c bearing lung tumours, 328 
caused by implantation of H226 cells. Mice were treated with the NP formulation by 329 
the pulmonary route using a microsprayer aerosoliser. Treatment resulted in a 330 
significant reduction in tumor burden, based on lung weight and more apoptopic 331 
cancer cells were presented in drug treated mice compared to controls.  This 332 
formulation was more effective than NP prepared using doxorubicin and octyl 333 
aldehyde. Data on drug entrapment for this formulation were not given but results 334 
from this study indicate that inclusion of a ligand that can bind to cells can improve 335 
drug targeting.  Two albumin NP formulations (termed Nab) have already been given 336 
FDA approval for clinical studies i.e. Nab paclitaxel (Nab-paclitaxel) for the treatment 337 
of metastatic breast cancer when used alone [54] or given in combination with 338 
carbinoplatin. The overall response rate (42% vs. 23%; p = 0.022), and tumour size 339 
shrinkage (37v% vs. 20%, p = 0.006), was higher in patients with visceral dominant 340 
disease treated with Nab-paclitaxel compared to paclitaxel alone. But there was no 341 
increase in the mean survival rate for Nab-paclitaxel treated patients compared to 342 
paclitaxel treatment alone. Nab-paclitaxel was however given a higher drug dose 343 
compared to paclitaxel alone (Nab-paclitaxel, 260 mg/m2 every 3 weeks, paclitaxel 344 
175 mg/m2 every three weeks).  Drug doses were not matched, as the objective of the 345 
study was to examine the efficacy and safety of Nab-paclitaxel versus paclitaxel in 346 
patients with poor prognostic factors. The two drugs had a similar toxicity profile but 347 
interestingly the NP formulation was more effective in patients A? ? ? years old (overall 348 
response rates Nab-paclitaxel 27 % vs. 19 % for paclitaxel; progression free survival 349 
5.6 vs. 3.5 months), which is important factor as elderly patients are now more 350 
common within populations [56, 57]. A more effective drug formulation for this cohort 351 
of patients would be beneficial. 352 
 353 
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NP can be made from polysaccharides such as chitosan, hyaluronate, cellulose, 354 
carrageenans, alginate or starch. Chitostan is a cationic polysaccharide usually 355 
produced from chitin by deaceylation. Chitin has a pKa of 6.2-6.8, and within an acidic 356 
environment (e.g. within tumour cells); chitosan can remain protonated and will swell.  357 
This would favour quick release of drug at the deposition site of drug-loaded NP. 358 
Chitostan NP loaded with the anticancer drug methylglyoxal, were small (50-100 nm), 359 
and had a net positive charge (+24 mV), and released their drug load within 10-12 360 
hours [58]. The small size of these NP may indicate that the NP have the potential to 361 
be exhaled once they are released into the airways from their aerosol droplet. 362 
Topotecan-loaded NP produced from chitosan were much larger, with a size of 642 363 
nm and a positive surface charge of 35 mV. These NP had a drug entrapment efficiency 364 
of 100% when a topetecan: chitosan ratio of 1:20 was used. In contrast a poly(D,1-365 
lactide-co-glycide or PGLA) and topetecan-loaded NP composite, where the NP were 366 
coated in PGLA resulted in a formulation with a lower entrapment efficiency (28%). 367 
This is probably due to drug loss when PGLA cross-linked to chitosan. The composite 368 
particles had a mean size of 2.1 µm and the surface charge dropped to -6.99 mV. A net 369 
negative charge may be beneficial as a positive surface charged has been associated 370 
with cytotoxicity for liposomes [59]. Drug release from the composite particles was 371 
much slower so that only 24% of the entrapped drug was released during the first 24 372 
hours, making these NP suitable for sustained drug release at their uptake site.  373 
 374 
Hyaluronate can also be used to improve targeting to cancer cells as it binds to CD44 375 
and CD168, markers upregulated on cancer cells [60]. NP loaded with paclitaxel and 376 
baicalcein, had a hydrophilic shell of hyaluronate and a hydrophobic core that 377 
contained the drugs.  The NP had a mean size of 92 nm and a zeta potential of + 3 mV 378 
and the nanoparticulate formulation was more toxic to A549 cells then paclitaxel/ 379 
baicalcein solution alone  (p < 0.05). Studies in a murine tumour model, where 380 
Kumming mice were injected with paclitaxel resistant A549 cells, showed that a single 381 
intravenous treatment dose significantly inhibited tumor growth (p < 0.05). In contrast 382 
similar treatment with the individual drugs had no significant effect on tumour size 383 
compared to controls. Only treatment of mice with paclitaxel or baicalcein solution 384 
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resulted in a noticeable reduction in weight compared to controls, indicating that the 385 
NP drug formulation had a lower toxicity to mice.  386 
 387 
Ethyl cellulose was used to produce NP by preparing using an oil in water emulsion 388 
solvent technique [60].  The resulting formulation was exposed to spray freeze-drying 389 
or spray drying, to produce nanocomposite microcarriers from the NP, which would 390 
break up to release the NP from the composite in an aqueous environment.  The initial 391 
NP had a mean size of 111 nm before spray drying or spray freeze-drying.  After 392 
spraying the nanocomposite microcarriers had a mean volume size of 7.2 µm using 393 
spray drying and 12.3 µm for spray freeze-drying. Spray freeze-drying gave particles 394 
that had a much larger surface area (77.6 vs. 2.4 m3/g) but the MMAD (2.4 µm vs. 3.1 395 
µm) and GSD (3.1 vs. 2.9) were very similar for the two spraying methods. 396 
Reconstitution of the nanocomposite microcarriers showed that spray freeze-drying 397 
gave a better formulation as it resulted in release of NP with a more uniform size [61]. 398 
The results indicate that this method could produce a NP based formulation that was 399 
suitable for pulmonary delivery, that could be administered as an inhalable dry-400 
powder. Ethyl cellulose or a mixture of ethyl and methyl cellulose were used to 401 
prepare NP that contained an extract from G. mangostana Linn, a tropical fruit from 402 
Southeast Asia [61]. The NP had a similar mean size of 253 and 250 nm respectively 403 
and a similar drug entrapment efficiencies (86 vs. 88%). NP prepared from ethyl 404 
cellulose had a more negative ɺ-potential (-31 vs. -12 mV respectively).  Both 405 
formulations were cytotoxic to HeLa cells, with NP prepared using ethyl cellulose being 406 
more cytotoxic (IC50 values 16.7 vs. 7.4 µg/ml). The corresponding extract-free NP had 407 
no toxicity against the cells at the doses used.  408 
 409 
NP were formed from alginate using poly(lactic-co-glycolic acid) [PLGA] and chitostan 410 
or poly(vinyl) alcohol [PVA]. Alginate/PLGA/chitostan NP had an entrapment efficiency 411 
of 71% (502H PGLA) or 80% (756 PGLA) whereas NP containing PVA instead of 412 
chitostan had an entrapment efficiency of 79% (502 H PGLA) or 61% (756 PGLA). NP 413 
that did not contain alginate had very poor drug entrapment (<10%), indicating that 414 
inclusion of alginate gave better drug loading. Tobramycin loading of these NP gave 415 
PV NP with a mean size of 300 nm whereas PGLA 756 NP were larger (400-500 nm). 416 
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Tobramycin loaded NP formed from alginate/PGLA/chitostan had a higher surface 417 
charge (20 to 40 mV) compared to NP formed from alginate/PGLA/PVA (approximately 418 
-5 mV). Both types of NP released tobramycin slowly so that drug was still present in 419 
the medium at day 40 in in vitro drug release studies. The two types of NP were loaded 420 
with rhodamine and produced as a dry powder using a spray drying method.  This 421 
method produced ůĂƌŐĞƌ ƐƚƌƵĐƚƵƌĞƐ ƚŚĂƚ ǁĞƌĞ ƚĞƌŵĞĚ  ?nano-embedded 422 
microparticles ?  ?ED ). The two types of NEM formulations had a similar MMAD 423 
(alginate/502 H PGLA/chitostan, 3.7; alginate/502 H PGLA/PVA, 3.7), with 424 
alginate/502 H PGLA/chitostan NEM having a higher FPF value (38 vs. 52% 425 
respectively). Rats were treated by the pulmonary route with the different NEM 426 
formulation using a breath-activated, reusable DPI to determine where they 427 
deposited in the lungs.  Rhodamine alginate/PGLA/chitostan NEM deposited 428 
rhodamine in the trachea, bronchia and bronchioles whereas alginate/PGLA/PVA NEM 429 
deposited rhodamine in the alveolar ducts and not the upper airways [62].  430 
 431 
There are a number of studies on using starch to prepare DDS, as it is one of the main 432 
dietary carbohydrates, and is therefore safe to use in humans. Starch was used to 433 
prepare funtionalized graphene nanosheets and loaded with hydroxycamptothecine 434 
(HCPT).  12 µg or HCPT could be loaded in to 150 µg of starch-graphene complex.  At 435 
the doses used, co-incubation of SW-620 cells had no cytotoxic effect against cells 436 
whereas treatment with HCPT-starch-graphene or HCPT were toxic to cells.   The drug 437 
solution was more effective but this could reflect the slow release of the drug from 438 
the graphene composite. Obviously for pulmonary delivery this type of complex would 439 
have to be manufactured into a suitable size and particle size for inhalation, and 440 
careful selection of the type of graphene to avoid toxicity is required [63].  441 
 442 
Conclusions  443 
Both NIV and NP produced from natural products can be used to deliver a variety of 444 
drugs by different routes including inhalation. In both cases a switch from batch 445 
manufacture to continuous manufacturing processes would facilitate large-scale 446 
production [64] and studies have shown that spray drying, which could be 447 
incorporated into such a method, is feasible for some formulations.  Lactose is often 448 
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used as a carrier to protect drugs against the harsh environmental conditions present 449 
during spray drying, and it often mixed with drug formulations to improve the 450 
flowability of powders administered using dry powder inhalers [65]. Therefore it is 451 
important to consider what type of device is going to be used for a drug formulation 452 
early on in its development to ensure that the appropriate type of formulation for the 453 
intended delivery device is developed. Three-dimension printing is an area that is 454 
actively being explored for production of production of novel drug formulations but 455 
achieving the small size required for production of nanoparticles is challenging, but 456 
not impossible. Nanoimprint lithography has been used to produce shape-specific 457 
solid NP with sizes of 50-400 nm [66]. And Cylindrical nanoparticles with a diameter 458 
of 240 or 125 nm have been produced using poly (acrylic acid), which could be used 459 
for aqueous or organic solvent-based imprint solutions [66]. Adapting 3-D printing 460 
methods to prepare NP from natural proteins or polysaccharides may be challenging, 461 
but alginate is already been used in preparing 3-D printed hydrogels, as it is a viscous 462 
non-toxic material that cross-linked in the presence of some divalent cations [68]. One 463 
major hurdle for translating a laboratory formulation into a clinical product is 464 
successful completion of preclinical toxicity testing.  However it is difficult predict 465 
whether a formulation will indeed be safe even if natural instead of synthetic, 466 
surfactants are used in the DDS as the entrapped therapeutic may be cytotoxic. 467 
However using a surfactant that is biocompatible with humans should reduce the 468 
inherent toxicity of the DDS.  At present healthcare providers are struggling to treat 469 
the high number of patients that use public health services, whilst meeting the 470 
constraints of their budget. Production of drug formulations or reformulation of 471 
existing drug for a non-invasive administration route could be a beneficial as it could 472 
reduce treatment costs if patients self-mediate rather than rely on in-patient service 473 
for drugs currently given by the parenteral route. Production of an effective drug 474 
formulation that can be given by inhalation may be facilitated by co-development of 475 
a nebuliser/drug formulation combination, to ensure that the formulation is deposited 476 
in the correct area of the respiratory tract for the particular disease indication.  477 
Technology to produce aerosols of drug formulations has changed to try and controls 478 
ƐŽŵĞ ŽĨ ƚŚĞ  ?ĚƌƵŐ-ĨƌĞĞ ? factors that can impact on therapeutic outcome, such as 479 
patient profile (adult versus pediatric use), device used, as well as correct use of the 480 
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inhalation device by the patient [16, 51, 56]. Therefore testing what impact using 481 
different nebulisers/inhalers has on pulmonary delivery should be an important 482 
consideration in the development of any inhaled drug formulation.  483 
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